Application of an Allosteric Agonist of the Luteinizing Hormone Receptor for Reducing the Effective Dose of Gonadotropin in the Treatment of Androgen Deficiency in Rats with Type 1 Diabetes

In type 1 diabetes mellitus, the impaired testosterone synthesis in testes leads to androgen deficiency. The long-term application of high gonadotropin doses for its correction decreases sensitivity luteinizing hormone/human chorionic (LH/hCG) receptors Leydig cells endogenous gonadotropins. aim this work was study effect a 3-day treatment male Wistar rats with streptozotocin 5-amino- N-tert -butyl-2-(methylsulfanyl)-4-(3-(nicotinamido) phenyl)thieno[2,3- d ]pyrimidine-6-carboxamide allosteric LH/hCG receptor agonist (TP03, 15 mg/kg/day) on steroidogenic effects relatively low-dose hCG (10 IU/rat, single dose, s.c.). Pretreatment diabetic TP03 enhanced stimulatory levels, slightly modifying expression proteins ( Star, Cyp11a1, Cyp17a1 ) and Lhr genes. Thus, diabetes, increases hCG, at same time as maintaining gene steroidogenesis enzymes testes.